Hannah E. O'FArrell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hannah E. O'FArrell has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Anne Bernadette Chang
Charles Darwin University Darwin Northern Territory Australia
5 shared publications - Ian Anthony Yang
The University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Brisbane, Australia
5 shared publications - Kwun Meng Fong
Department of Thoracic Medicine, The Prince Charles Hospital, University of Queensland Thoracic Research Centre, Brisbane, Australia
5 shared publications - Julie Maree Marchant
Centre for Healthcare Transformation Australian Centre for Health Services Innovation Queensland University of Technology Brisbane
3 shared publications Rayleen V. Bowman
UQ Thoracic Research Centre, Faculty of Health, Medicine and Behavioural Sciences The University of Queensland Brisbane Australia
3 shared publications- Stephanie T. Yerkovich
Queensland University of Technology, South Brisbane, Australia
3 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 104 (1) , 59
Neutrophil-related gene expression profile is associated with future paediatric bronchiectasis exacerbations
Acute respiratory exacerbations in bronchiectasis are important as they impair quality of life and are associated with accelerated lung function decline. Yet, no validated methods exist to identify children at increased risk of exacerbations. We therefore determined if peripheral blood gene expression (GE) signatures can identify those at risk of an impending exacerbation. Thirty-one children with bronchiectasis had RNA extracted from peripheral blood collected whilst they were clinically stable, with 22 having an exacerbation during the next 3 months. Microarray assays using the HumanHT-12 v4.0 Expression BeadChip identified differentially expressed genes ( p value ≤ 0.05, fold change > 1.5). The top targets were verified using real-time quantitative polymerase chain reaction (rt-qPCR) assays, and receiver operating characteristics and area under the curve (AUC) were assessed. Functional analysis of these genes was performed using Ingenuity Pathway Analysis. Overall, 647 entities were significantly dysregulated ( p < 0.05) in the exacerbation group ( n = 22), and pathway analysis identified neutrophil degranulation as the dominant affected pathway, which was also significantly inhibited ( p < 0.001). Forty entities (32 genes) were associated with a future exacerbation ( p ≤ 0.05, fold change ≥ 1.5) and six genes ( ANXA3 , ALAS2 , DEFA1 , ALPL , SNCA , PROK2 ) were verified using RT-qPCR (all p < 0.04) as the most discriminatory. DEFA1 and ANXA3 had the highest AUC (0.92, 95% confidence interval [CI] 0.82–1.00, and 0.87, 95% CI 0.73–1.00, respectively). We identified neutrophil-associated genes from peripheral blood that could be potential biomarkers for children with bronchiectasis at increased risk of exacerbations during the next 3 months. These GE signatures warrant further investigation and validation in larger, independent cohorts. Key messages: Exacerbations in paediatric bronchiectasis are important. Peripheral blood gene expression may help identify children at risk of exacerbations. Six neutrophil-associated genes were associated with a future exacerbation. Identifying predictive gene expression signatures warrants further investigation.
- 1 April 2026
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 104 (1) , 59
Open AccessNeutrophil-related gene expression profile is associated with future paediatric bronchiectasis exacerbations
Acute respiratory exacerbations in bronchiectasis are important as they impair quality of life and are associated with accelerated lung function decline. Yet, no validated methods exist to identify children at increased risk of exacerbations. We therefore determined if peripheral blood gene expression (GE) signatures can identify those at risk of an impending exacerbation. Thirty-one children with bronchiectasis had RNA extracted from peripheral blood collected whilst they were clinically stable, with 22 having an exacerbation during the next 3 months. Microarray assays using the HumanHT-12 v4.0 Expression BeadChip identified differentially expressed genes ( p value ≤ 0.05, fold change > 1.5). The top targets were verified using real-time quantitative polymerase chain reaction (rt-qPCR) assays, and receiver operating characteristics and area under the curve (AUC) were assessed. Functional analysis of these genes was performed using Ingenuity Pathway Analysis. Overall, 647 entities were significantly dysregulated ( p < 0.05) in the exacerbation group ( n = 22), and pathway analysis identified neutrophil degranulation as the dominant affected pathway, which was also significantly inhibited ( p < 0.001). Forty entities (32 genes) were associated with a future exacerbation ( p ≤ 0.05, fold change ≥ 1.5) and six genes ( ANXA3 , ALAS2 , DEFA1 , ALPL , SNCA , PROK2 ) were verified using RT-qPCR (all p < 0.04) as the most discriminatory. DEFA1 and ANXA3 had the highest AUC (0.92, 95% confidence interval [CI] 0.82–1.00, and 0.87, 95% CI 0.73–1.00, respectively). We identified neutrophil-associated genes from peripheral blood that could be potential biomarkers for children with bronchiectasis at increased risk of exacerbations during the next 3 months. These GE signatures warrant further investigation and validation in larger, independent cohorts. Key messages: Exacerbations in paediatric bronchiectasis are important. Peripheral blood gene expression may help identify children at risk of exacerbations. Six neutrophil-associated genes were associated with a future exacerbation. Identifying predictive gene expression signatures warrants further investigation.
- Open Access
- 11 March 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (3) , e70517
Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma
Background: Liquid biopsy has emerged as a promising, minimally invasive tool to detect cancer biomarkers. Extracellular vesicles (EVs) are secreted into biofluids to transport cargo such as DNA and are a potential biosource for liquid biopsy biomarkers. To determine the optimal use of liquid biopsy for diagnosing mutations in lung adenocarcinoma (LUAD), we compared the KRAS mutation status in DNA isolated from four different plasma fractions, including EVs. Methods: Plasma was collected from 58 participants diagnosed with LUAD (early‐stage (I, II), n = 30; late‐stage (IIIB, IV), n = 28) with known KRAS mutation ( KRAS mt ) or wild‐type KRAS ( KRAS wt). Three distinct plasma‐derived fractions were prepared by sequential differential ultracentrifugation aiming to isolate EVs (pellets 1, 2, 3 (P1–P3)). These were tested together with the corresponding plasma supernatant (SUP) for the presence of KRAS G12/G13 mutations by droplet digital PCR (ddPCR). Results: In early‐stage KRAS mt LUAD, mutations were detected by ddPCR in only 1 of 15 processed plasma supernatant samples and 1 of 15 P3 samples, but not in any P1 or P2 pellets. In late‐stage KRAS mt LUAD, mutations were detected in 13/14 of SUP samples, but only in a small fraction of the pellet preparations: P1 (0/14), P2 (2/14) and P3 (2/13) samples. Conclusion: We conclude that ddPCR testing of plasma supernatant achieved high overall agreement with tumour KRAS mt status. There was varying abundance of KRAS detected in the plasma fractions.
- 11 March 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (3) , e70517
Open AccessComparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma
Background: Liquid biopsy has emerged as a promising, minimally invasive tool to detect cancer biomarkers. Extracellular vesicles (EVs) are secreted into biofluids to transport cargo such as DNA and are a potential biosource for liquid biopsy biomarkers. To determine the optimal use of liquid biopsy for diagnosing mutations in lung adenocarcinoma (LUAD), we compared the KRAS mutation status in DNA isolated from four different plasma fractions, including EVs. Methods: Plasma was collected from 58 participants diagnosed with LUAD (early‐stage (I, II), n = 30; late‐stage (IIIB, IV), n = 28) with known KRAS mutation ( KRAS mt ) or wild‐type KRAS ( KRAS wt). Three distinct plasma‐derived fractions were prepared by sequential differential ultracentrifugation aiming to isolate EVs (pellets 1, 2, 3 (P1–P3)). These were tested together with the corresponding plasma supernatant (SUP) for the presence of KRAS G12/G13 mutations by droplet digital PCR (ddPCR). Results: In early‐stage KRAS mt LUAD, mutations were detected by ddPCR in only 1 of 15 processed plasma supernatant samples and 1 of 15 P3 samples, but not in any P1 or P2 pellets. In late‐stage KRAS mt LUAD, mutations were detected in 13/14 of SUP samples, but only in a small fraction of the pellet preparations: P1 (0/14), P2 (2/14) and P3 (2/13) samples. Conclusion: We conclude that ddPCR testing of plasma supernatant achieved high overall agreement with tumour KRAS mt status. There was varying abundance of KRAS detected in the plasma fractions.
- Open Access
- 5 February 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003606
Improving the management and outcomes of preschool wheeze: protocol of a prospective multicentre cohort study
Introduction: Preschool wheeze and asthma are associated with substantial morbidity and impaired future lung function. Yet, wheeze is unreliably reported with high disagreement (>50%) between parental and physician observations. Objectively defining wheeze and its reversibility could enable an earlier asthma diagnosis and improve preschool wheeze management. Our primary aim is to determine in preschool children (aged 0.5–6 years) suspected of asthma whether adding WheezeScan to routine clinical assessment (vs assessment without WheezeScan) improves the diagnosis of asthma. Our primary hypothesis is that using WheezeScan in preschool children suspected of asthma is associated with increased definitive asthma diagnoses in this age group. Our secondary aims are to (a) examine the effect of using WheezeScan on patient-reported outcomes (PROs) and (b) healthcare costs. Our secondary hypothesis is that using WheezeScan in preschool children suspected of asthma is associated with improved quality of life without incurring additional healthcare costs. Methods and analysis: Our multicentre prospective cohort study involves recruiting 102 preschool children suspected of asthma. WheezeScan, a user-friendly digital device, incorporates artificial intelligence to objectively define wheeze and its response to bronchodilators. Over 6 weeks, parents/caregivers use the WheezeScan two times per day and whenever wheezing is suspected. If wheeze is detected, an inhaled short-acting β 2 -agonist is administered and WheezeScan determines if wheeze resolves thereafter. Our primary endpoint is the proportion of children with a definitive asthma diagnosis, compared with baseline, based on the treating clinician’s assessment using WheezeScan data. Our secondary outcomes are PROs, reflecting generic health-related quality-of-life and cough-specific (if chronic cough present) outcomes and health costs. Ethics and dissemination: The Children’s Health Queensland Human Research Ethics Committee (HREC/23/QCHQ/100691) and the Queensland University of Technology Office of Research Ethics and Integrity approved the study. We will publish and share results with the academic and healthcare communities and relevant patient organisations. Trial registration number: Australian New Zealand Clinical Trials Registry ACTRN12623000904673.
- 5 February 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003606
Open AccessImproving the management and outcomes of preschool wheeze: protocol of a prospective multicentre cohort study
Introduction: Preschool wheeze and asthma are associated with substantial morbidity and impaired future lung function. Yet, wheeze is unreliably reported with high disagreement (>50%) between parental and physician observations. Objectively defining wheeze and its reversibility could enable an earlier asthma diagnosis and improve preschool wheeze management. Our primary aim is to determine in preschool children (aged 0.5–6 years) suspected of asthma whether adding WheezeScan to routine clinical assessment (vs assessment without WheezeScan) improves the diagnosis of asthma. Our primary hypothesis is that using WheezeScan in preschool children suspected of asthma is associated with increased definitive asthma diagnoses in this age group. Our secondary aims are to (a) examine the effect of using WheezeScan on patient-reported outcomes (PROs) and (b) healthcare costs. Our secondary hypothesis is that using WheezeScan in preschool children suspected of asthma is associated with improved quality of life without incurring additional healthcare costs. Methods and analysis: Our multicentre prospective cohort study involves recruiting 102 preschool children suspected of asthma. WheezeScan, a user-friendly digital device, incorporates artificial intelligence to objectively define wheeze and its response to bronchodilators. Over 6 weeks, parents/caregivers use the WheezeScan two times per day and whenever wheezing is suspected. If wheeze is detected, an inhaled short-acting β 2 -agonist is administered and WheezeScan determines if wheeze resolves thereafter. Our primary endpoint is the proportion of children with a definitive asthma diagnosis, compared with baseline, based on the treating clinician’s assessment using WheezeScan data. Our secondary outcomes are PROs, reflecting generic health-related quality-of-life and cough-specific (if chronic cough present) outcomes and health costs. Ethics and dissemination: The Children’s Health Queensland Human Research Ethics Committee (HREC/23/QCHQ/100691) and the Queensland University of Technology Office of Research Ethics and Integrity approved the study. We will publish and share results with the academic and healthcare communities and relevant patient organisations. Trial registration number: Australian New Zealand Clinical Trials Registry ACTRN12623000904673.
- Open Access
- 12 March 2025
- Published by IOP Publishing in Journal of Breath Research
- Vol. 19 (2) , 026009
Assessing the feasibility of breath collection from conscious young children to support volatilome analysis: insights into age limitations and breath sampling requirements
Breath volatile organic compounds (VOCs) are increasingly under consideration as biomarkers of respiratory disease. Although numerous studies have identified VOCs that distinguish patient groups, a lack of standardisation among published studies has impeded translation into clinical diagnostics. Standardised breath collection protocols have been proposed for adults and children aged >4 years, but optimal methods for collecting breath from younger children remain to be determined. The aim of this study was to assess the feasibility and acceptability of breath sampling among a young paediatric cohort. A total of 61 children (age 6 months–12 years) were recruited prospectively to observational studies of chronic cough at two study sites. Mixed expiratory breath was collected into 1 l Tedlar Bags using either a drinking straw, mouthpiece, or mask. After concentrating onto thermal desorption tubes, the breath was analysed using two-dimensional gas chromatography coupled with time-of-flight mass spectrometry. Breath collection via a mouthpiece was highly feasible for children aged >2 years. Mask-based collection was required for younger children but was poorly tolerated. Drinking straw-based collections were unsuitable for some children aged <4 years due to challenges maintaining a sufficient seal. At least 700 ml of breath was sampled from 72.6% of children. The number of peaks per sample, total peak area per sample, and composition of breath VOCs were all consistent with successful breath sampling. The high feasibility of breath collection via a mouthpiece in our study suggests established protocols designed for children aged over 4 years can be used with confidence for children from as young as 2 years of age.
- 12 March 2025
- Published by IOP Publishing in Journal of Breath Research
- Vol. 19 (2) , 026009
Open AccessAssessing the feasibility of breath collection from conscious young children to support volatilome analysis: insights into age limitations and breath sampling requirements
Breath volatile organic compounds (VOCs) are increasingly under consideration as biomarkers of respiratory disease. Although numerous studies have identified VOCs that distinguish patient groups, a lack of standardisation among published studies has impeded translation into clinical diagnostics. Standardised breath collection protocols have been proposed for adults and children aged >4 years, but optimal methods for collecting breath from younger children remain to be determined. The aim of this study was to assess the feasibility and acceptability of breath sampling among a young paediatric cohort. A total of 61 children (age 6 months–12 years) were recruited prospectively to observational studies of chronic cough at two study sites. Mixed expiratory breath was collected into 1 l Tedlar Bags using either a drinking straw, mouthpiece, or mask. After concentrating onto thermal desorption tubes, the breath was analysed using two-dimensional gas chromatography coupled with time-of-flight mass spectrometry. Breath collection via a mouthpiece was highly feasible for children aged >2 years. Mask-based collection was required for younger children but was poorly tolerated. Drinking straw-based collections were unsuitable for some children aged <4 years due to challenges maintaining a sufficient seal. At least 700 ml of breath was sampled from 72.6% of children. The number of peaks per sample, total peak area per sample, and composition of breath VOCs were all consistent with successful breath sampling. The high feasibility of breath collection via a mouthpiece in our study suggests established protocols designed for children aged over 4 years can be used with confidence for children from as young as 2 years of age.
- Open Access
- 28 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 756
Endotypes of Paediatric Cough—Do They Exist and Finding New Techniques to Improve Clinical Outcomes
Chronic cough is a common symptom of many childhood lung conditions. Given the phenotypic heterogeneity of chronic cough, better characterization through endotyping is required to provide diagnostic certainty, precision therapies and to identify pathobiological mechanisms. This review summarizes recent endotype discoveries in airway diseases, particularly in relation to children, and describes the multi-omic approaches that are required to define endotypes. Potential biospecimens that may contribute to endotype and biomarker discoveries are also discussed. Identifying endotypes of chronic cough can likely provide personalized medicine and contribute to improved clinical outcomes for children.
- 28 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 756
Open AccessEndotypes of Paediatric Cough—Do They Exist and Finding New Techniques to Improve Clinical Outcomes
Chronic cough is a common symptom of many childhood lung conditions. Given the phenotypic heterogeneity of chronic cough, better characterization through endotyping is required to provide diagnostic certainty, precision therapies and to identify pathobiological mechanisms. This review summarizes recent endotype discoveries in airway diseases, particularly in relation to children, and describes the multi-omic approaches that are required to define endotypes. Potential biospecimens that may contribute to endotype and biomarker discoveries are also discussed. Identifying endotypes of chronic cough can likely provide personalized medicine and contribute to improved clinical outcomes for children.
- Open Access
- 25 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 4879
Cough Hypersensitivity Syndrome: Why Its Use Is Inappropriate in Children
In children and adults, chronic cough is a common symptom presenting to health professionals worldwide. It is internationally accepted that children with chronic cough should be managed with pediatric specific management guidelines. The newly proposed clinical entity of ‘cough hypersensitivity syndrome’ has gained significant attention in adult literature. Given the significant differences between childhood and adult chronic cough, including in respiratory physiology and anatomy, and cough sensitivity, we address the suitability of the use of cough hypersensitivity syndrome in children. We explore these differences between childhood and adult chronic cough, explain what cough hypersensitivity is and highlight why the term cough hypersensitivity syndrome should not be used in children.
- 25 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 4879
Open AccessCough Hypersensitivity Syndrome: Why Its Use Is Inappropriate in Children
In children and adults, chronic cough is a common symptom presenting to health professionals worldwide. It is internationally accepted that children with chronic cough should be managed with pediatric specific management guidelines. The newly proposed clinical entity of ‘cough hypersensitivity syndrome’ has gained significant attention in adult literature. Given the significant differences between childhood and adult chronic cough, including in respiratory physiology and anatomy, and cough sensitivity, we address the suitability of the use of cough hypersensitivity syndrome in children. We explore these differences between childhood and adult chronic cough, explain what cough hypersensitivity is and highlight why the term cough hypersensitivity syndrome should not be used in children.
- Open Access
- 4 November 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 2821-2833
Plasma Extracellular Vesicle miRNA Profiles Distinguish Chronic Obstructive Pulmonary Disease Exacerbations and Disease Severity
Purpose: Molecular biomarkers for chronic obstructive pulmonary disease (COPD) severity have been difficult to identify. We aimed to assess extracellular vesicle miRNAs’ potential as a blood biomarker in discriminating disease severity in participants with COPD. Patients and Methods: Plasma extracellular vesicles (EVs) were obtained from two COPD cohorts (n = 20 during an exacerbation event, n = 20 during stable state), with varying disease severity (GOLD stages). The miRCURY LNA miRNA Serum/Plasma assay, specific to 179 targets, was used to evaluate EV miRNA expression. The miRNAs that were significantly dysregulated were further assessed for discriminatory power using ROC curve analysis, as well as their role in relevant biological pathways. Results: One miRNA was significantly dysregulated between moderate GOLD participants compared to severe/very severe GOLD participants, with an AUC of 0.798, p = 0.01 for miR-374b-5p. Five miRNAs were significantly dysregulated between exacerbating and stable COPD participants, with miR-223-3p resulting in the highest AUC (0.755, p = 0.006) for a single miRNA, with a combination of three miRNAs (miR-92b-3p, miR-374a-5p and miR-106b-3p) providing the highest discriminatory power (AUC 0.820, p = 0.001). The “cytokine–cytokine receptor interaction” (hsa04060 pathway) was the most significant KEGG pathway enriched for three out of the five miRNAs associated with COPD exacerbations. Conclusion: This initial small-scale study suggests that the bioactive cargo (miRNAs) in plasma EVs holds specific biological information for the severity of airflow obstruction and COPD exacerbations, warranting further investigation.
- 4 November 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 2821-2833
Open AccessPlasma Extracellular Vesicle miRNA Profiles Distinguish Chronic Obstructive Pulmonary Disease Exacerbations and Disease Severity
Purpose: Molecular biomarkers for chronic obstructive pulmonary disease (COPD) severity have been difficult to identify. We aimed to assess extracellular vesicle miRNAs’ potential as a blood biomarker in discriminating disease severity in participants with COPD. Patients and Methods: Plasma extracellular vesicles (EVs) were obtained from two COPD cohorts (n = 20 during an exacerbation event, n = 20 during stable state), with varying disease severity (GOLD stages). The miRCURY LNA miRNA Serum/Plasma assay, specific to 179 targets, was used to evaluate EV miRNA expression. The miRNAs that were significantly dysregulated were further assessed for discriminatory power using ROC curve analysis, as well as their role in relevant biological pathways. Results: One miRNA was significantly dysregulated between moderate GOLD participants compared to severe/very severe GOLD participants, with an AUC of 0.798, p = 0.01 for miR-374b-5p. Five miRNAs were significantly dysregulated between exacerbating and stable COPD participants, with miR-223-3p resulting in the highest AUC (0.755, p = 0.006) for a single miRNA, with a combination of three miRNAs (miR-92b-3p, miR-374a-5p and miR-106b-3p) providing the highest discriminatory power (AUC 0.820, p = 0.001). The “cytokine–cytokine receptor interaction” (hsa04060 pathway) was the most significant KEGG pathway enriched for three out of the five miRNAs associated with COPD exacerbations. Conclusion: This initial small-scale study suggests that the bioactive cargo (miRNAs) in plasma EVs holds specific biological information for the severity of airflow obstruction and COPD exacerbations, warranting further investigation.
- Open Access
- 14 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (24) , 5856
Burden of Care for Children with Bronchiectasis from Parents/Carers Perspective
Bronchiectasis is a neglected chronic respiratory condition. In children optimal appropriate management can halt the disease process, and in some cases reverse the radiological abnormality. This requires many facets, including parental/carer bronchiectasis-specific knowledge, for which there is currently no such published data. Further, the importance of patient voices in guiding clinical research is becoming increasingly appreciated. To address these issues, we aimed to describe the voices of parents of children with bronchiectasis relating to (a) burden of illness and quality of life (QoL), (b) their major worries/concerns and (c) understanding/management of exacerbations. The parents of 152 children with bronchiectasis (median age = 5.8 years, range 3.5–8.4) recruited from the Queensland Children’s Hospital (Australia) completed questionnaires, including a parent-proxy cough-specific QoL. We found that parents of children with bronchiectasis had impaired QoL (median 4.38, range 3.13–5.63) and a high disease burden with median 7.0 (range 4.0–10.0) doctor visits in 12-months. Parental knowledge varied with only 41% understanding appropriate management of an exacerbation. The highest worry/concern expressed were long-term effects (n = 42, 29.8%) and perceived declining health (n = 36, 25.5%). Our study has highlighted the need for improved education, high parental burden and areas of concern/worry which may inform development of a bronchiectasis-specific paediatric QoL tool.
- 14 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (24) , 5856
Open AccessBurden of Care for Children with Bronchiectasis from Parents/Carers Perspective
Bronchiectasis is a neglected chronic respiratory condition. In children optimal appropriate management can halt the disease process, and in some cases reverse the radiological abnormality. This requires many facets, including parental/carer bronchiectasis-specific knowledge, for which there is currently no such published data. Further, the importance of patient voices in guiding clinical research is becoming increasingly appreciated. To address these issues, we aimed to describe the voices of parents of children with bronchiectasis relating to (a) burden of illness and quality of life (QoL), (b) their major worries/concerns and (c) understanding/management of exacerbations. The parents of 152 children with bronchiectasis (median age = 5.8 years, range 3.5–8.4) recruited from the Queensland Children’s Hospital (Australia) completed questionnaires, including a parent-proxy cough-specific QoL. We found that parents of children with bronchiectasis had impaired QoL (median 4.38, range 3.13–5.63) and a high disease burden with median 7.0 (range 4.0–10.0) doctor visits in 12-months. Parental knowledge varied with only 41% understanding appropriate management of an exacerbation. The highest worry/concern expressed were long-term effects (n = 42, 29.8%) and perceived declining health (n = 36, 25.5%). Our study has highlighted the need for improved education, high parental burden and areas of concern/worry which may inform development of a bronchiectasis-specific paediatric QoL tool.